AstraZeneca's Brilique (ticagrelor) approved in Europe
This article was originally published in Scrip
AstraZeneca's ticagrelor has been approved by the European Commission for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) in combination with aspirin. The second rival to the clot-busting blockbuster Plavix (clopidogrel) will be known in Europe by the trade name Brilique. It joins Lilly's prasugrel (Efient/Effient) which was approved in Europe and the US last year.